# Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma

> **NCT07148245** · — · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 300 (estimated)

## Conditions studied

- Cutaneous Melanoma
- Cutaneous Melanoma, Stage III
- Cutaneous Melanoma by AJCC V7 Stage
- Cutaneous Melanoma, Stage IV

## Interventions

- **PROCEDURE:** Blood Sample
- **OTHER:** Health Related Quality of Life Questionnaires (HRQoL)
- **OTHER:** Medical Chart Review

## Key facts

- **NCT ID:** NCT07148245
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-13
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07148245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07148245, "Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07148245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*